Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | ERN1 | O75460 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17397902 | 0.91 | LMNA (0.47) | LMNAHPGDERN1MAPK1ALDH1A1 | |
| SCHEMBL17397880 | 0.85 | ERN1 (0.40) | ERN1MAPK1P2RX7 | |
| SCHEMBL20861592 | 0.85 | ERN1 (0.40) | LMNAHPGDERN1MAPK1P2RX7 | |
| SCHEMBL22802070 | 0.83 | LPL (0.33) | ERN1MAPK1P2RX7 | |
| SCHEMBL20861614 | 0.80 | LMNA (0.34) | LMNAHPGDERN1 | |
| SCHEMBL25078221 | 0.78 | P2RX7 (0.35) | MAPK1P2RX7 | |
| SCHEMBL30486658 | 0.76 | LPL (0.35) | MAPK1P2RX7 | |
| SCHEMBL20408805 | 0.76 | MAPK1 (0.34) | MAPK1P2RX7 | |
| SCHEMBL15335320 | 0.76 | LPL (0.35) | MAPK1P2RX7 | |
| SCHEMBL17397885 | 0.73 | KDM4E (0.33) | HPGDERN1MAPK1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3164404-B1 | TRICYCLIC BENZOXABOROLES AS ANTIBACTERIAL AGENTS | DAIICHI SANKYO CO LTD (JP) | 2019-04-03 | — | — | EP | disclosed |
| EP-3164404-B1 | TRICYCLIC BENZOXABOROLES AS ANTIBACTERIAL AGENTS | DAIICHI SANKYO CO LTD (JP) | 2019-04-03 | — | — | EP | disclosed |
| US-9944660-B2 | Tricyclic benzoxaboroles as antibacterial agents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-04-17 | — | — | US | disclosed |
| US-9944660-B2 | Tricyclic benzoxaboroles as antibacterial agents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-04-17 | — | — | US | disclosed |
| US-9944660-B2 | Tricyclic benzoxaboroles as antibacterial agents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-04-17 | — | — | US | disclosed |
| US-20170174709-A1 | TRICYCLIC BENZOXABOROLES AS ANTIBACTERIAL AGENTS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-06-22 | — | — | US | disclosed |
| US-20170174709-A1 | TRICYCLIC BENZOXABOROLES AS ANTIBACTERIAL AGENTS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-06-22 | — | — | US | disclosed |
| US-20170174709-A1 | TRICYCLIC BENZOXABOROLES AS ANTIBACTERIAL AGENTS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-06-22 | — | — | US | disclosed |
| EP-3164404-A1 | TRICYCLIC BENZOXABOROLES AS ANTIBACTERIAL AGENTS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-05-10 | — | — | EP | disclosed |
| WO-2016001834-A1 | TRICYCLIC BENZOXABOROLES AS ANTIBACTERIAL AGENTS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-07 | — | — | WO | disclosed |
| WO-2016001834-A1 | TRICYCLIC BENZOXABOROLES AS ANTIBACTERIAL AGENTS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174709-A1 | TRICYCLIC BENZOXABOROLES AS ANTIBACTERIAL AGENTS | REN, ALPI, IKBKE | LMNA 1859/4885HPGD 2190/4885ERN1 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.